Elopag (Eltrombopag) 25 MG – 14 Tablets

Elopag (Eltrombopag) 25 mg use to rise the number of platelets (cells that help the blood clot) to down the risk of bleeding in young and children 1 year of age and older who have chronic immune thrombocytopenia (ITP; an ongoing condition that cause unusual bruising or bleeding due to an abnormally little number of platelets in the blood) and who not to help or cannot treatment with other treatments, including medications or surgery to remove the spleen. Elopag also use to rise the number of platelets in people who have hepatitis C (a viral infection that damage the liver) so that they can begin and continue to treat with interferon (Peginterferon, Pegintron, others) and ribavirin (Rebetol). Eltrombopag further also use in combination with other medications to treat aplastic anemia (condition in which the body does not make enough new blood cells) in adults and children 2 years of age and older. This is use to treat aplastic anemia in adults who not to help with different medications. Elopag like a class of medications call thrombopoietin receptor agonists. It blocks causing the cells in the bone marrow to produce more platelets.

Use of Elopag

Elopag use to treat:

• Low platelet levels due to chronic immune thrombocytopenia (ITP). This is a bleeding disorder. Eltrombopag is given to people who haven’t responded well to other drugs or surgery.
• Low platelet counts due to chronic hepatitis C virus infection. This drug is used before and during treatment with the drug pegylated interferon and ribavirin.
• Severe aplastic anemia. Aplastic anemia is when you have bone marrow failure, which results in low levels of platelets, red blood cells, and white blood cells. Eltrombopag use in two ways for this condition:
  • First-line treatment of severe aplastic anemia. This drug can be used as the first treatment option in some cases of severe aplastic anemia. For this use, eltrombopag is given in combination with other initial treatments.
  • Treatment of refractory severe aplastic anemia. Some cases of severe aplastic anemia are refractory, which means the anemia did not improve after treatment with other medications. Eltrombopag can be used alone for treating these cases of anemia.

Eltrombopag not use to treat myelodysplastic syndrome (MDS).

How it works

Elopag belongs to a class of drugs called thrombopoietin (TPO) receptor agonists. A class of drugs is a group of medications that work in a similar way. These drugs often use to treat similar conditions.

Eltrombopag works by increasing cells in your bone marrow. It causes these cells to make more platelets. This effect lowers your risk of bleeding. If you have any signs of unusual bleeding or bruising while taking eltrombopag, call your doctor right away. Your doctor may tell you to stop taking this drug if you’re also taking blood-thinning medications.

Elopag side effects

Elopag can cause mild or serious side effects. The following list contains some of the key side effects that may occur while taking eltrombopag. This list does not include all possible side effects.

For more information on the possible side effects of eltrombopag, or tips on how to deal with a troubling side effect, talk with your doctor or pharmacist.

More common side effects

The more common side effects of Elopag can include:

• Anemia
• Nausea
• Fever
• Tiredness
• Cough
• Headache
• Diarrhea
• Flu
• Loss of appetite

If these effects are mild, they may go away within a few days or a couple of weeks. If they’re more severe or don’t go away, talk to your doctor or pharmacist.

Interactions that increase your risk of side effects

Increased side effects from other drugs: Taking eltrombopag with certain medications raises your risk of side effects from these drugs. Examples of these drugs include:

• Bosentan, ezetimibe, glyburide, olmesartan, repaglinide, rifampin, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, sulfasalazine, and topotecan. Your doctor may lower your dosage of these drugs if needed.
• Cholesterol-lowering drugs such as rosuvastatin, atorvastatin, fluvastatin, pitavastatin, pravastatin, and simvastatin. Increased side effects can include muscle pain. Your doctor may lower the dosage of your cholesterol drugs.

Interactions of medicine effective

When use with Elopag, these drugs can make eltrombopag less effective. This means it won’t work as well to treat your condition. This is because the amount of eltrombopag in your body may be decreased. Examples of these drugs include:

• Antacids, vitamins, or supplements that contain calcium, aluminum, iron, selenium, zinc, or magnesium. To avoid interactions, you should take eltrombopag two hours before or four hours after taking any of these products.

Disease progression warning

If you have myelodysplastic syndrome (MDS), this drug can cause your condition to progress to acute myeloid leukemia (AML). For people with MDS, this drug also increases the risk of death. Don’t use this drug if you have MDS.

Blood clots warning

This drug increases platelet counts. This may cause blood clots. If you have other blood clot risk factors, ask your doctor if this drug is safe for you.

Cataracts warning

This drug may cause cataracts (a clouding of the lens in your eyes). If you already have cataracts, this drug may make your condition worse. Your doctor will give you an eye exam before starting your treatment with this drug. They will also check you for signs of eye problems during treatment. If you develop cataracts, your doctor will lower your dosage or stop your treatment with this drug.

Allergy warning

This drug can cause a severe allergic reaction. Symptoms can include:

• Trouble breathing
• Swelling of your throat or tongue
• Skin rash
• Itchiness

Don’t take this drug again if you’ve ever had an allergic reaction to it. Taking it again could be fatal (cause death).

Food interactions warning

Foods that contain calcium may make Elopag less effective. These foods include dairy products, such as milk and cheese. Take this drug at least two hours before eating calcium-rich foods, or four hours after eating calcium-rich foods.

Warnings for certain health conditions

Myelodysplastic syndrome (MDS): This drug can cause your condition to progress to acute myeloid leukemia (AML). It also raises your risk of death. Don’t use this drug if you have MDS.

Liver problems: If you have liver problems or a history of liver disease, you may not be able to process this drug well. This medication may also decrease your liver function, making your liver disease worse. Ask your doctor if this medication is safe for you.

Blood clotting disorders: This drug may increase your risk of blood clots. Ask your doctor if this medication is safe for you.

Warnings for other groups

Pregnant women

There haven’t enough studies done in humans to be certain how this drug might affect a pregnancy. Research in animals has shown negative effects to the pregnancy when the mother takes the drug. However, animal studies don’t always predict the way humans would respond.

Talk to your doctor if you’re pregnant or planning to become pregnant. This drug should only use if the potential benefit justifies the potential risk.

If you become pregnant while taking this drug, call your doctor right away.

Breastfeeding women

This medication not recommend for use while breastfeeding. This drug may pass into breast milk and cause side effects in a child who is breastfed. Talk to your doctor if you breastfeed your child. You may need to decide whether to stop breastfeeding or stop taking this medication.

Seniors

If you’re older than 65 years, you may have a higher risk of side effects from this drug. Your kidneys and liver may process drugs more slowly. As a result, a higher amount of a drug stays in your body for a longer time. This raises your risk of side effects.

Children

This drug has not studied in children younger than 1 year with chronic immune thrombocytopenia. It should not use in children younger than 1 year for this condition.

This drug has not studied in children younger than 2 years with definitive immunosuppressive therapy-naïve severe aplastic anemia (in combination with other medications). It should not use in children younger than 2 years for this condition. (Therapy naïve means the condition has not been treated before.)

This drug has not established as safe or effective for use in children with thrombocytopenia associated with chronic hepatitis C virus infection and refractory severe aplastic anemia. It should not use in people younger than 18 years with these conditions.

If miss a dose

If you miss a dose, wait and take your next scheduled dose. Do not take more than one dose of this drug in one day.